Zoltan Laboratories LLC (ZL) is poised to play a
a major role in developing a drug to prevent or reverse
unintended weight loss (cachexia) experienced by
many cancer patients. Such drug would significantly
enhance the efficacy of cancer therapy and ensure a
better quality of life of these patients. Presently there
are no truly effective anticachectic agents available
for the clinical practice.
ZL's drug candidate, tested in many chemotherapy- treated tumor models, promises to be more effective and safer than currently available drugs to prevent weight loss in cancer patients.
As part of its general protective function, ZL's drug candidate also helps to achieve glycemic control and prevent excess body weight gain in animal models of diabetes. ZL strives to exploit these effects to enhance the efficacy of standard treatments directed at about 10-15% of cancer patients who are also diabetic.
ZL maintains close relationships with CanCure Laboratories LLC and Essential SkinCare LLC.
ZL's drug candidate, tested in many chemotherapy- treated tumor models, promises to be more effective and safer than currently available drugs to prevent weight loss in cancer patients.
As part of its general protective function, ZL's drug candidate also helps to achieve glycemic control and prevent excess body weight gain in animal models of diabetes. ZL strives to exploit these effects to enhance the efficacy of standard treatments directed at about 10-15% of cancer patients who are also diabetic.
ZL maintains close relationships with CanCure Laboratories LLC and Essential SkinCare LLC.